Accéder au contenu principal

Remplissez les détails pour débloquer le webinaire

En continuant, vous acceptez nos Conditions d'utilisation, notre Politique de confidentialité et le fait que vos données sont stockées aux États-Unis.

Haut-parleurs

Entreprises

Formation de 2 personnes ou plus ?

Donnez à votre équipe l’accès à la bibliothèque DataCamp complète, avec des rapports centralisés, des missions, des projets et bien plus encore
Essayer DataCamp pour les entreprisesPour une solution sur mesure , réservez une démo.

Adding Value in Pharma Through Data & AI Transformation

February 2024
Webinar Preview

Summary

In the pharmaceutical sector, data and AI transformation initiatives are vital for staying competitive. Industry specialists, including Tracy Ring from Accenture, Christian Bourne-Durhouse from Durhouse Consulting, and Gabriel Eichler from Oak Health Partners, highlighted the strategic importance of AI in enhancing commercial research, development, and supply chain procedures. They underscored the significance of a well-outlined strategy that aligns with wider enterprise objectives, and the necessity for data comprehension across organizations. The conversation also touched on the hurdles of expanding AI initiatives, the subtleties of regulatory compliance, and the potential of synthetic data. Success experiences from firms like Novartis demonstrated the transformative effect of utilizing AI to unlock business value while managing complex regulatory requirements.

Key Takeaways:

  • AI and data changes should be in line with enterprise strategies for maximum effect.
  • Successful transformation initiatives often focus more on individuals and procedures than on technology.
  • Data understanding and AI knowledge across organizations are vital for effective transformation.
  • Regulatory compliance, especially the European AI Act, presents significant challenges for AI deployment.
  • Synthetic data can be an effective tool in addressing regulatory challenges and enhancing AI capabilities.

Deep Dives

Strategic Alignment with Enterprise Goals

Tracy Ring from Accenture stresses that any data and AI transformation initiative must start with a transparent strategy that is closely related to the wider objectiv ...
Lire La Suite

es of the enterprise. This multi-dimensional method involves talent, technology, and process reinvention, ensuring that AI initiatives are not seen as isolated technology projects but are integrated into the business's core objectives. "We're building muscles and the technological infrastructure to support transformation," she notes. This strategic alignment ensures that AI efforts are sustainable and can deliver long-term value.

People and Processes Over Technology

Christian Bourne-Durhouse and Gabriel Eichler highlight that while technology is a critical component of transformation, the real challenges often lie in people and processes. Bourne-Durhouse mentions that transformation initiatives should not be viewed purely as technology initiatives but require significant changes in business processes and culture. Eichler adds that "radiologists who use AI will replace those who don't," highlighting the importance of integrating AI into existing workflows rather than replacing human roles. This method not only enhances efficiency but also ensures that AI adoption is smooth and sustainable.

Regulatory Challenges and Compliance

The pharmaceutical industry's stringent regulatory environment presents unique challenges for AI deployment. Eichler discusses the complexities of regulatory compliance, particularly with the upcoming European AI Act, which will require extensive documentation and transparency for AI systems. The Act's global implications mean that companies must prepare to meet these standards, or face significant fines. As Christian Bourne-Durhouse notes, "Pharma needs to have capabilities themselves, not only rely on partners," emphasizing the need for organizations to build in-house expertise in managing these regulatory requirements.

The Role of Synthetic Data

Synthetic data is emerging as a critical tool in overcoming regulatory hurdles and expanding AI capabilities. Tracy Ring highlights its importance, especially in areas with limited data availability, such as rare diseases. By creating non-human copies of data, synthetic data allows organizations to test and validate AI models without violating privacy regulations. This method not only aids in compliance but also accelerates innovation by providing a safe environment for experimentation. As Eichler notes, the use of synthetic data "can be a powerful alternative to having the actual data," offering a way to utilize AI's full potential while adhering to regulatory requirements.

Connexe

infographic

Data Literacy for Responsible AI

Learn how data literacy fuels responsible AI

webinar

Scaling Data & AI Literacy with a Persona-Driven Framework

In this session, three experts walk you through the steps of creating a successful data training program.

webinar

Scaling Data & AI Literacy with a Persona-Driven Framework

In this session, three experts walk you through the steps of creating a successful data training program.

webinar

How AI Can Improve Your Data Strategy

Find out how AI, ML, and data science can inform your data strategy.

webinar

Artificial Intelligence for Business Leaders

We'll answer the questions about AI that you've been too afraid to ask.

webinar

Spreading Data & AI Literacy Across Your Organization

Learn how to devise a data and AI strategy that aligns with your business strategy, and how to combine technology and training to increase the data and AI literacy across your company for business success.